REN and cardiac hypertrophy: Possible mechanisms include irbesartan inhibiting the renin–angiotensin–aldosterone system (RAAS), reducing the level of AngII and blocking the binding of AngII to AT1R to improve the metabolism of myocardial fibroblasts and reduce myocardial hypertrophy.